title: Inhibition of nischarin expression attenuates rilmenidine-evoked hypotension and phosphorylated extracellular signal-regulated kinase 1/2 production in the rostral ventrolateral medulla of rats.
abstract: Imidazoline (I(1))-evoked hypotension is linked to enhanced phosphorylated extracellular signal-regulated kinase (pERK)1/2 production in the rostral ventrolateral medulla (RVLM). Recent cell culture findings suggest that nischarin is a candidate for the I(1) receptor. In the present study, nischarin antisense oligodeoxynucleotide (ODN) (AS1 or AS2), designed according to nischarin cDNA sequence, was administered intracisternally (i.c., 2 nmol/rat for 2 days) to knockdown central nischarin expression; control rats received the corresponding mismatched ODN (MM1 or MM2) or artificial cerebrospinal fluid (aCSF). We investigated the effects of AS1 or AS2 on nischarin expression in the RVLM, and on the hypotension and RVLM pERK1/2 production elicited by the I(1)-selective agonist rilmenidine (25 mug/rat i.c.). Compared with aCSF, the mismatched ODN (MM1 or MM2) had no significant effect on RVLM nischarin expression or the cardiovascular and cellular (RVLM pERK1/2) responses elicited by rilmenidine. However, either antisense ODN substantially (>80%) reduced nischarin expression in the RVLM (AS1/MM1, 3 +/- 1 versus 32 +/- 2 positive cells; AS2/MM2, 4 +/- 1 versus 31 +/- 2 positive cells) and abrogated rilmenidine (I(1))-evoked hypotension (AS1/MM1, -4.1 +/- 0.9 versus -10.8 +/- 1.9 mm Hg; AS2/MM2, -2.1 +/- 1.1 versus -15.3 +/- 2.5 mm Hg) and ERK1/2 activation in the RVLM (AS1/MM1, 10 +/- 1 versus 15 +/- 2 positive cells; AS2/MM2, 9 +/- 1 versus 18 +/- 2 positive cells). Finally, pERK1/2 generated by central I(1) receptor activation is colocalized with nischarin in the RVLM neurons. This is the first evidence in vivo that nischarin plays a critical role in I(1) receptor-mediated pERK1/2 production in the RVLM and the subsequent hypotension.
authors.affiliation: Department of Pharmacology and Toxicology, Brody School of Medicine, East Carolina University, Greenville, NC 27834, USA.
authors.forename: Jian
authors.initials: J
authors.lastname: Zhang
authors.forename: Abdel A
authors.initials: AA
authors.lastname: Abdel-Rahman
mesh_terms: D000818:Animals; D000959:Antihypertensive Agents; D001794:Blood Pressure / Q000187:drug effects; D006339:Heart Rate / Q000187:drug effects; D007022:Hypotension / Q000139:chemically induced / Q000378:metabolism*; D047908:Intracellular Signaling Peptides and Proteins / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology*; D008297:Male; D008526:Medulla Oblongata / Q000187:drug effects / Q000502:physiology*; D019950:Mitogen-Activated Protein Kinase 1 / Q000378:metabolism*; D048052:Mitogen-Activated Protein Kinase 3 / Q000378:metabolism*; D020319:Oligodeoxyribonucleotides, Antisense / Q000494:pharmacology; D010080:Oxazoles; D010766:Phosphorylation; D051381:Rats; D017207:Rats, Sprague-Dawley; D000077769:Rilmenidine
chemical_list: D000959:Antihypertensive Agents; D047908:Intracellular Signaling Peptides and Proteins; C519767:Nisch protein, rat; D020319:Oligodeoxyribonucleotides, Antisense; D010080:Oxazoles; D019950:Mitogen-Activated Protein Kinase 1; D048052:Mitogen-Activated Protein Kinase 3; D000077769:Rilmenidine